Top in cardiology: Avocado intake and CVD risk, P2Y12 inhibitors vs. aspirin
Click Here to Manage Email Alerts
Eating at least two servings of avocado per week may lower the risk for CVD and coronary heart disease when compared with no avocado consumption, according to a recent study.
Researchers found that the risk for CVD was lowered by 20% for every half-serving increase in avocado intake per day. However, findings showed that avocado consumption was not linked to a lower risk for stroke. It was the top story in cardiology last week.
Another top story reported on P2Y12 inhibitor monotherapy and its advantages over aspirin monotherapy for secondary CVD prevention. According to researchers, the risk for major adverse cardiovascular (CV) events, such as stroke, MI or death, was reduced by 11% among patients who received P2Y12 inhibitor monotherapy compared with aspirin monotherapy.
Read these and more top stories in cardiology below:
Two servings of avocado per week may lower risk for CVD, CHD
Two servings of avocado per week, compared with not eating any avocado, was associated with lower risk for CVD and coronary heart disease, but not stroke, researchers reported. Read more.
P2Y12 inhibitors may be superior to aspirin for secondary CVD prevention
In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported. Read more.
Warmer summer nights confer elevated risk for CV death in certain men
Warmer summer nights were associated with increased risk for CV death in men aged 60 to 64 years, researchers reported in BMJ Open. Read more.
‘Stroke-heart syndrome’ increases 5-year risk for CV events, death
New-onset CV complications after ischemic stroke predicts worse 5-year prognosis for major adverse CV events, including death, according to new research published in Stroke. Read more.
Updated guideline redefines HF stages, emphasizes prevention, new treatments
A joint guideline from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America redefines HF stages to focus on prevention and recommends HF treatment with SGLT2 inhibitors. Read more.